{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:45:00Z","timestamp":1770047100182,"version":"3.49.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medullary thyroid cancer (MTC) accounts for approximately 4% of thyroid carcinomas. Patients with unresectable, metastatic disease are candidates for approved agent-targeted therapies such as vandetanib, cabozantinib, or selpercatinib, but toxicity is often an issue. Preclinical data supported the potential use of immunotherapy targeting carcinoembryonic antigen (CEA) in this indolent disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with advanced\/recurrent MTC were randomly assigned in a 1:1 ratio to receive a Saccharomyces cerevisiae (yeast)-based immunotherapy (GI-6207) targeting CEA starting at the time of enrollment or 6\u2009months after surveillance. The primary endpoint was to compare the calcitonin growth rate in the GI-6207 arm at 6\u2009months with patients in the surveillance arm at 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between March 2013 and May 2018, 34 patients were randomly assigned to receive the yeast-CEA vaccine (GI-6207) starting at the time of enrollment or 6\u2009months after surveillance. The mean age was 51\u2009years, and 82% of patients were diagnosed with sporadic MTC. There was no significant change in the calcitonin growth rates at 6\u2009months when the immunotherapy group was compared with the surveillance group (\u22122.490042 vs \u22122.526385; P\u2009=\u2009.3760). Treatment with GI-6207 was associated with increased peripheral CEA-specific CD4 and\/or CD8 T cells, with 15\/26 (58%) patients displaying increases after 3\u2009months of treatment. One patient had a significant inflammatory event 17\u2009months after the last vaccine at a known lymph node, perhaps related to a delayed immune response. There were no grade 3 or 4 adverse events. Grade 1 injection site reactions were most common.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The immunotherapy was well tolerated but did not have an impact on tumor growth rate at 6\u2009months as measured by calcitonin kinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Identification<\/jats:title>\n                    <jats:p>NCT01856920<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf429","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:44:24Z","timestamp":1767098664000},"source":"Crossref","is-referenced-by-count":0,"title":["A phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4030","authenticated-orcid":false,"given":"Jaydira","family":"Del Rivero","sequence":"first","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee N","family":"Donahue","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L","family":"Marte","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Gramza","sequence":"additional","affiliation":[{"name":"Medstar Georgetown Lombardi Comprehensive Cancer Center , Washington, DC 20057,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijo","family":"Bilusic","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-4084","authenticated-orcid":false,"given":"Lisa","family":"Cordes","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Schlom","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026020200312159800_oyaf429-B1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026020200312159800_oyaf429-B2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.vaccine.2007.11.033","article-title":"Recombinant saccharomyces cerevisiae (yeast-cea) as a potent activator of murine dendritic cells","volume":"26","author":"Bernstein","year":"2008","journal-title":"Vaccine"},{"key":"2026020200312159800_oyaf429-B3","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1158\/1078-0432.CCR-08-0393","article-title":"Vaccination with a recombinant saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses","volume":"14","author":"Wansley","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026020200312159800_oyaf429-B4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1634\/theoncologist.2010-0129","article-title":"Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","volume":"15","author":"Madan","year":"2010","journal-title":"Oncologist"},{"key":"2026020200312159800_oyaf429-B5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00262-013-1505-8","article-title":"Phase i trial of a recombinant yeast-CEA vaccine (gi-6207) in adults with metastatic CEA-expressing carcinoma","volume":"63","author":"Bilusic","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2026020200312159800_oyaf429-B6","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/j.annonc.2024.08.1695","article-title":"1614p psa responses and psma scan changes after immunotherapy for biochemically recurrent prostate cancer (bcr) without androgen deprivation therapy (adt)","volume":"35","author":"Madan","year":"2024","journal-title":"Annals of Oncology"},{"key":"2026020200312159800_oyaf429-B7","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.1016\/j.annonc.2020.08.940","article-title":"Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer","volume":"31","author":"Madan","year":"2020","journal-title":"Annals of Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf429\/66159765\/oyaf429.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf429\/66159765\/oyaf429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf429\/66159765\/oyaf429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:31:30Z","timestamp":1770010290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf429\/8407308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf429","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,30]]},"article-number":"oyaf429"}}